JUVISÉ-PHARMACEUTICALS
The French pharmaceutical company, Juvisé Pharmaceuticals, announces the acquisition of global commercial rights (excluding the United States and Canada) to Ponvory® (ponesimod) from Actelion Pharmaceuticals Ltd., a Johnson & Johnson Company (Johnson & Johnson). Ponvory® is indicated for the treatment of adults with active forms of relapsing multiple sclerosis (RMS); it is protected by several patents, the latest of which expires in 2035. To fund this acquisition, the French sovereign fund Bpifrance and Pemberton Asset Management (‘Pemberton’), a leading European private credit manager, have acquired a minority stake in Juvisé Pharmaceuticals. Financial details of these transactions remain undisclosed.
“We are very excited about Ponvory® and its potential to have a very positive impact on the lives of patients with multiple sclerosis” announces Frédéric Mascha, founder and President of Juvisé Pharmaceuticals. “This acquisition is a strategic step for Juvisé as it expands our portfolio with the first patent protected product with strong development potential over the coming years. It is in line with what we have been doing for the past 16 years, which is providing essential medications to patients and specialist doctors. Following our latest partnerships established with Novartis, AstraZeneca and AbbVie, we are proud to establish a new partnership with a major pharmaceutical company and to have two strong partners such as Bpifrance and Pemberton enter our capital to support our future growth.”
The acquisition of Ponvory®: a strategic move in Juvisé Pharmaceuticals' growth strategy
Multiple Sclerosis (MS) is a chronic autoimmune pathology affecting over 2.5 million patients worldwide and enjoys therapeutic innovation.
Ponvory® (ponesimod) is a first-line treatment option in active forms of relapsing multiple sclerosis (RMS), which is the most common form of the disease (approximately 80% of patients), affecting particularly women around the age of 30-years-old. Ponvory® is the first oral Disease Modifying Treatment (DMT) to demonstrate superior efficacy compared to teriflunomide in a large head-to-head Phase III study (OPTIMUM) in adult patients with active RMS. Ponvory® demonstrated a 30.5% reduction in Annualized Relapse Rate (primary endpoint), as well as reduction in MRI activity and fatigue (secondary endpoints). (1)
Juvisé Pharmaceuticals will leverage its expertise in medical affairs, marketing, and distribution to commercialize and develop Ponvory® outside of the United States and Canada, with a focus on Europe, skills that the company has already demonstrated with the successful European relaunch of Pylera® in 2023. Juvisé Pharmaceuticals will work closely with Johnson & Johnson to ensure a seamless transition and continuous availability of Ponvory® for patients. Ponvory® is currently available in 30 countries, with the objective of expanding this scope. Finally, Juvisé Pharmaceuticals will assume the worldwide manufacturing duties for Ponvory® from sites based in France and Switzerland.
Juvisé Pharmaceuticals opens its capital to Bpifrance and Pemberton
The acquisition of Ponvory® is funded by a mix of capital increase, additional debt, and shareholder loan.
Bpifrance, the French sovereign fund financing businesses in their development, and Pemberton, a leading European private credit manager, have acquired a minority stake in Juvisé as part of the transaction.
About Juvisé Pharmaceuticals
Since its creation in 2008, Juvisé Pharmaceuticals has played a pivotal role in enhancing patient care by providing access to treatments with high medical value. Juvisé re-prioritized essential medicines in oncology (breast and prostate cancer), cardiology, gastroenterology, neuropsychiatry, and rheumatology, making them accessible to over 4.4 million patients every year. Juvisé Pharmaceuticals is present through its products in 80 countries in the world on five continents and relocates the production of its acquired medications in Europe, with 81% being manufactured in Europe and 51% in France. In 2024, Juvisé Pharmaceuticals revenues are expected to reach about 180M€ (+38% vs 2023) with PONVORY® accounting for about 24%.
For more information, visit www.juvisepharmaceuticals.com
Lazard acted as financial advisor to Juvisé Pharmaceuticals and its shareholders.
Bird & Bird, Latham & Watkins and Bredin Prat acted as legal counsel to Juvisé Pharmaceuticals.
Société Générale remains the lead banking partner for Juvisé Pharmaceuticals.
1. Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdová EK, Hennessy B, Hohlfeld R, Lublin F, Montalban X, Pozzilli C, Scherz T, D'Ambrosio D, Linscheid P, Vaclavkova A, Pirozek-Lawniczek M, Kracker H, Sprenger T. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. JAMA Neurol. 2021 May 1;78(5):558-567. doi: 10.1001/jamaneurol.2021.0405. PMID: 33779698; PMCID: PMC8008435
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325471791/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom